Warning Letters Issued to Illegally Sold Diabetes Treatments

Recently, FDA launched an initiative to counter these illegally sold products aimed at consumers who have diabetes. In addition to evaluating numerous consumer complaints, FDA surveyed the marketplace for illegally sold products promising to treat diabetes and its complications. In July 2013, FDA issued letters warning 15 companies about selling products for diabetes in violation of federal law. These products are sold as dietary supplements;

Read more

Illegally Sold Diabetes Treatments Are A Far-Reaching Problem

There are 26 million people in the U.S. who have diabetes, including about 7 million who are undiagnosed, according to the Centers for Disease Control and Prevention. Millions more have pre-diabetes, meaning they have higher than normal blood sugar levels and can reduce their risks of developing diabetes through healthy lifestyle changes, including diet and exercise. “Products that promise an easy fix might be alluring,

Read more

When Given Control Over Monitoring And Medication, High-Risk Patients Are Able To Lower Their Blood Pressure

A new study finds that patients with hypertension who are given control over monitoring their blood pressure as well as making adjustments to their medications are better able to lower their systolic blood pressure than those who use convention treatment. Aimed at those with diabetes, chronic kidney disease or other major cardiovascular risk factors, the study from researchers in the United Kingdom found that putting

Read more

Type 2 Drug Slashes Dementia Risk

A new study has surprising implications for a generic diabetes drug. Pioglitazone, which is often prescribed for patients with Type 2 diabetes, also appears to reduce the risk of developing dementia. The drug was not studied specifically to see if cut the incidence of Alzheimer’s disease and dementia. Instead, researchers from the German Center for Neurodegenerative Diseases combed through a giant database of German health

Read more

BI-Lilly Alliance Creates Formidable Drug Development Combine

Pharma giants Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) have formed the BI-Lilly Diabetes Alliance, a joint effort, involving the development of several drugs aimed at treating type 1 and type 2 diabetes patients. The Alliance recently showed up in force at the 74th American Diabetes Association Scientific Sessions in San Francisco, June 13-17. It made more than 40 presentations on drugs and

Read more

FDA Approves New Neuropathy Pain Drug

The US Food and Drug Administration has approved US sales of NUCYNTA® ER (tapentadol), a twice-daily extended-release oral analgesic for the treatment of pain from diabetic peripheral neuropathy. The drug, produced by New Jersey-based Janssen Pharmaceuticals, Inc., provides around-the-clock management for moderate to severe chronic neuropathic pain. Janssen says that it is currently the only opioid on the US market that has been approved for

Read more

Newly Diagnosed with Type 2 Diabetes? Be Sure Your Doctor Prescribes a Generic First

According to a study of patients newly diagnosed with type 2 diabetes, 35 percent of the time their physicians did not follow the American Diabetes Association (ADA) guideline that calls for prescribing a generic drug first. The study, conducted by researchers from CVS Caremark, Harvard University, and Brigham and Women’s Hospital, reviewed the pharmacy claims of 254,000 patients who were started on a diabetes medication

Read more